Select Medical Holdings Corporation Price & Performance (SEM)

These forward looking statements are based on the information available to management of Select Medical Medical today and the company assumes no obligation to update these statements as circumstances change. At this time, I will turn the conference call over to Mr. Robert Ortencio.

Thank you, operator. Good morning, everyone. Welcome to Select Medical's earnings call for the fourth quarter of twenty twenty four.

The fourth quarter concluded a very busy year at Select.

On November 25 Select, we completed the spin off of Concentra via special stock distribution Select Medical shareholders Select.

I'd like to thank all of our colleagues at Select and Concentra for their tremendous dedication hard work to complete this transaction. The historical results of Concentra are now reflected as discontinued operation in Select's consolidated financial statements.

We will focus our results for the fourth quarter on the remaining three lines of business, which exclude Concentra. Also during the quarter on December 3, we completed a refinancing of $1,600,000,000 of Select Medical's outstanding debt. We issued 1,050,000,000.00 in new seven year term loans and $550,000,006.25 senior notes due 02/1932. We'll use the proceeds together with cash on hand to repay our then existing $373,000,000 in term loans and 1,225,000,000.000 in senior notes due August 2026. We also paid related fees and expenses associated with the financing. Interest rate on the new term loans is so far plus 2%. In addition, we extended the maturity of our revolving credit facility to 2029 and increase the availability on the revolver from $550,000,000 to $600,000,000 Our credit agreement leverage was 3.18 times at 12/31/2024.

On the development front, we added 94 inpatient rehabilitation beds in the fourth quarter. We acquired a 50 bed inpatient rehab hospital in Oklahoma City, on December 10 with our joint venture partner SSM. We also opened two neuro transitional units with 12 beds each one in Dallas with our joint venture partner, Baylor Scott and White, and the other in Dublin, Ohio our joint venture partner OhioHealth.

Concurrently with the opening of the Dublin Neurotransitional Center, we also added 20 rehab beds to the Dublin Rehab Hospital which is also part of our joint venture. With OhioHealth. As mentioned on our last call, we have additional development projects in various stages for the inpatient rehab division which I will summarize again. In January, we opened acute rehab unit in Madison, Wisconsin, Wisconsin with 18 beds.

Q2, we plan on opening a 45 bed rehab hospital in Temple, Texas. As well as our second hospital with UPMC 20 beds in Central Pennsylvania. In Q3, we'll open our fourth rehab hospital with the Cleveland Clinic in Fairhill, Ohio with 32 beds. In Q1 of twenty twenty six, we plan to open our fourth rehab hospital as part of our joint venture with Banner in Tucson, Arizona.

Which will be 58 beds, and a new freestanding 63 bed rehab hospital in Ozark, Missouri with Cox Health Systems. In Q4, twenty twenty six, new 60 bed rehab hospital in Southern New Jersey the Baccarat Institute for Rehab in partnership with AtlantiCare is scheduled to open as well as a new 68 bed facility in Jersey City New Jersey branded as Kessler.

Between the specific projects just mentioned as well as some other smaller expansions and new acute rehab units in existing hospitals, we plan to add four eighty one additional beds to our operations 2025 and 2026. Additional beds will consist of four fifty five inpatient rehab beds which includes 68 non consolidating beds and 26 There are also a number of other opportunities under evaluation that would further increase our select specialty hospital footprint. This quarter, our outpatient rehab division added three de novo clinics and four clinics through acquisition. This was offset by the strategic closure or consolidation of 18 locations with limited growth potential. We're continually evaluating and identifying areas of opportunity to optimize resources in serving our patient population and targeted demographics. Now I'll turn to our financial results. Overall, we had another strong quarter all three of our divisions exceeding prior year revenue in the fourth quarter with combined revenue increase of 8%. Adjusted EBITDA also grew by 4 percent $111,800,000 to $116,000,000 The three remaining divisions returned impressive growth year over year. For the full year, revenue grew from continuing operations with 7% and adjusted EBITDA growth was 14%.

Adjusted EBITDA from continuing operations was $510,400,000.0 with a 9.8% adjusted EBITDA margin compared to $446,100,000 and 9.2% margin in 2023. We are very pleased with Q4 performance of our critical illness recovery hospital division with a 6% increase in revenue a 10% increase in adjusted EBITDA and a 4% increase in adjusted EBITDA [indiscernible] to the same quarter prior year. Our occupancy rate increased from 66% to 67% compared to prior year Q4. Rate per day increased by 7% and our adjusted EBITDA margin was 10.5% for the quarter compared to 10.1% in prior year Q4. Critical illness salary wages and benefits to revenue ratio was 57% an improvement of 1.2% compared to prior year Q4.

As we have mentioned previously, we have seen nursing agency rates stabilize and utilization return to pre COVID levels.

Our utilization of agency nurses remain the same as prior year Q4 at 14%. Nursing sign on incentive bonus dollars are again lower than prior year showing a 15% reduction for the fourth quarter and a 20% reduction year over year. We continue to expand our inpatient rehab hospital division with three additional facilities and a 13% increase in revenue when compared to prior year Q4.

Adjusted EBITDA declined by 6% and adjusted EBITDA margin was 21.2%, which was lower than the prior period margin The primary reason for the reduction of EBITDA compared to prior year is related to startup losses. In our new facilities, integration costs related to our acquisition in Oklahoma City and a drop in referrals from one of our key partners that was impacted by Hurricane Alleyne thus far in Q1 of twenty twenty five, referrals from this partner are back to normal. Average daily census for the entire rehab division increased 3% and our rate per patient day increased 6%. Our occupancy of 81% was 4% lower than prior year of eighty five percent which is primarily a result of our new hospitals. Our outpatient rehab division continues to improve from prior year, with increases in all areas for the final quarter of twenty twenty four. The division saw an increase of 7% in revenue 4% in patient volume 2% in net revenue per visit and 18% in adjusted EBITDA from prior year Q4. Net revenue per visit increased from $100 prior year Q4 to 102 with the continued improvements in commercial rates to despite declines in Medicare reimbursement. The Outpatient division's adjusted EBITDA margin increased from 7.5% to 8.3% as the team continues to focus on improving patient access, productivity and staffing.

We're able to see positive results despite two hurricanes Alain and Milton in the fourth quarter of this year impacting a number of our Southern outpatient markets. We believe the negative EBITDA impact to be slightly over $1,000,000 with thankfully no material property damage or extended clinic closures. Our dilution loss per common share from continuing operations was $0.19 for the fourth quarter compared to earnings per common share from The Adjusted EBITDA adjusted EPS from continuing operations was $0.18 compared to adjusted EPS of $0.12 for the same quarter prior year. Adjusted EPS excludes the loss on early retirement of debt the one time acceleration of stock comp expense and costs related to the Concentra transaction.

For the full year, earnings per share from continuing operations was $0.51 compared to $0.46 per share in the prior year. And adjusted earnings per share from continuing operations was $0.94 compared to adjusted EPS of $0.54 in the prior year. In regards to our allocation of deployment of capital, our Board has declared a cash dividend of $6.02 $5 per share the close of business on 03/03/2025. This past quarter, we did not repurchase shares under our Board authorized share repurchase program and we'll continue to evaluate stock repurchases, reduction of debt and development development opportunities. At this point, turn it over to Marty Jackson, who'll continue to provide some details. Thanks, Bob. Good morning, everyone. I will begin by providing additional details on the progress we can As mentioned above, we believe that the cost and utilization of agency nurses has normalized.

Overall, our SW and B as a percentage of revenue was 56.9% this quarter, which has decreased from 57.6% in Q4 of prior year. [indiscernible] improvement in the margin was driven by controlling internal labor costs and an increase in the net revenue per [indiscernible] Nursing sign on and incentive bonus dollars decreased by 15% from Q4 of prior year. From $7,400,000 to $6,300,000 are pleased with the continued progress we have made in regards to labor costs and critical illness, and finished the year with SW and B as a percentage of revenue at 55.9% compared to 57.2% in 'twenty three. Moving on to our financials. At the end of the quarter, we had $1,700,000,000 of debt outstanding. And $59,700,000 of cash on the balance sheet.

Our debt balance at the end of the quarter included $1,050,000,000 in term loans $105,000,000 in revolving loans, dollars $550,000,000 in six in the quarter senior notes, which are due 2,032 and $26,300,000 of other miscellaneous debt. As previously mentioned, we ended the quarter with net leverage for our senior secured credit agreement of 3.18 times. As of December 31, we had $453,300,000 of availability on a revolving loan.

The interest rate on our term loan Sober plus 200 basis points and this matures December 3, '20 In interest expense was $28,600,000 in the fourth quarter This compares to $40,300,000 in the same quarter prior year. The decrease in interest expense was due to the reduction of Select's debt resulting from the Concentra IPO and related debt transaction in the third quarter of this year. Using the proceeds of these transactions, we were able to prepay $1,600,000,000 on the existing term loan. And pay down the revolver balance. For the fourth quarter, operating activities provided 100 and and $25,400,000 in cash flow. Our day sales outstanding or DSO for continued operations excluding Concentra was fifty eight days at 12/31/2024, this compares to fifty five days December 31, 2023, sixty days at 09/30/2024, sixty two days at March 31, 2024. We continue to see improvement in our DSO every quarter as the claims processing pack log that resulted from the change healthcare [indiscernible] earlier in 2024 resolved itself. Investing activities used $74,200,000 of cash in the fourth quarter. This includes $63,400,000 in purchases of property and equipment and $10,800,000 in acquisition and investment activity. Financing activities used $183,000,000 of cash in the In the fourth quarter, the use of cash included all the net financing transactions described [indiscernible] as well as cash transferred to Concentra.

At separation. Additional activity included include $16,000,000 in dividends of our common stock, dollars 20,000,000 in repurchases of common stock, dollars 25,000,000 in net repayments on other debt, and $18,000,000 in net distributions and purchases of non controlling [indiscernible] As stated previously, we did not repurchase any shares under our Board authorized repurchase program this quarter. The Board approved share repurchase program remains in effect until 12/31/2025. Unless further extended or earlier terminated by the Board. We are issuing our business outlook for 2025 And Select and expect revenue to be in the range of $5,400,000,000 to $5,600,000,000 Adjusted EBITDA is expected to be in the range of $520,000,000 to $540,000,000 And finally, adjusted earnings per common share is expected to fall in the range of $1.09 to $1.19 Capital expenditures are expected to be in the range of $160,000,000 to $200,000,000 This concludes our prepared remarks. And at this time, we would like to turn it back to the operator to open up the call for questions. Our first question comes from Justin Bowers with Deutsche Bank. Hey, good morning everyone. So, I think there's a little confused out there in the market, because of what's in and out of consensus and [indiscernible] Concentra's partially still in the numbers.

Just to level set for 2025, I'm arriving at the midpoint of revenue growth of, call it, 6% EBITDA growth of 4% and then EPS growth of 6% and a 4Q exit call it 3.18 turns net leverage. Is that is that are those sort of the right metrics here? Yes, Justin, hold on just for a second.

We'll go through the calculations make sure that your numbers are correct. But as we do that, let me let me address I'm glad you brought it up. We do believe that there's some significant confusion in the marketplace at this time. And I think what the issue is [indiscernible] think a number of people have added at have not removed Concentra From consensus.

So I mean if you take a look at as you know, As you know, Concentra had announced preannounced their numbers. If you take a look at those numbers on an annual basis, You would have 800 on a revenue basis, north of $7,000,000,000 $7,870,000,000 which exceeds consensus by 8%. On an EBITDA basis, $887,400,000 which exceeds consensus by [indiscernible] And I'll also point out that it exceeds our if you recall, we gave annual estimates it exceeds those estimates on both revenue and EBITDA. Of the revenue and the EBITDA line. So from that perspective, yes, there is some confusion.

All right. So on a consolidated basis, go ahead.

Yes. The combined revenue increase that that we have is about [indiscernible] we're talking about '25 Yes, we're talking about 25. So we're going to have to get this calculation. So go ahead with your question.

Okay. So [indiscernible] going back to all the development, I mean this is the most active that Select has been You have increasing your IRF bed count by north of 30% over the next two years. Can you remind us how those facilities sort of mature [indiscernible] [indiscernible] [indiscernible] the number of startup costs maybe in the fourth quarter and 2025 as well?

Yes. That's a very good point. And you're right.

I mean, the we're north of 30% increase in beds over the next eighteen months.

And quite candidly, that's really having a dampening effect in particular, on the inpatient rehab margins for 25% in which you'll see is that they actually because of the model that we have, the joint venture model, they mature pretty quickly. So you can expect to see those turnaround and see some very significant double digit EBITDA growth in 'twenty six and 'twenty seven.

Okay. That's helpful. And then [indiscernible] I'm just doing some math here on the development activity. I'm sort of arriving at like a new growth algo of top line growth mid single digit plus, EBITDA growth probably up in that high singles.

And then EPS and free cash flow growth well in per share well into the double digits before really deploying any of the excess free cash flow. Is that the right neighborhood?

Yes. I think that's the right one. So should you think of the model over the next three years or so?

The way I'd like to take a look at it, Justin, I'd like to take a look at Off of 25, I would expect to see double digit EBITDA growth I think in the teens range, Because of all the new beds coming on board. Okay.

And that's consolidated?

That's just for the Inpatient Rehab side.

In your segment. Okay. All right.

Okay. We also expect we I would think on the on the in pay or on the LTACH side, you should expect some pretty slow growth there. I mean, I would expect low single digit And then on the outpatient side, I would also expect to see some double digit growth on EBITDA in 2025 and 2026.

All right. That is helpful. I will jump back in queue. Thank you. Thanks, Justin. Next question will come from the line of Ben Hendrix with RBC Capital Markets.

Hey, thank you very much. I appreciate the color on your refinancing. And year end leverage, but in acknowledging that there's been some confusion kind of post spend, but maybe you can get an idea, you can give us an idea of your kind of go forward post separation leverage targets, how you're thinking about the gearing for this company? And kind of where we are versus the kind of the optimal debt load? Thanks. Yes, Ben. Thanks for the question.

Our expectation is Given the Given the high activity in particular in the inpatient rehab side, I mean we expect to remain in that three to 3.1 time [indiscernible] 25 as far as leverage is concerned. But we would expect to be well below that come 26 and beyond.

Appreciate that. And just to follow-up, a question on the inpatient it looks like margins were a little lower this quarter. It sounds like there were some development costs in there. And maybe were there any other kind of headwinds transitory or otherwise that may have kind of caused a little bit of a depression on the IRF side this quarter versus last several? Yes. At one of our hospitals, one of our referral sources was Impact by the Hurricane Helene. And their census was suppressed So, correspondingly, our census was suppressed at that facility. What we've seen in 2025 is census is back to normal. So we believe that was anomaly, but that along with the startup losses the integration costs for our acquisition, that's what contributed to the decrease in margin year over year for the inpatient rehab. Great. Thank you for that clarification. Thanks, Vin. Our next question comes from the line of Joanna Gascuk with Bank of America. So just I guess a little bit of follow-up to that last comment about the IRF margins. And as as it relates to the twenty twenty five outlook, your guidance, you implies margins would decline about 20 basis points or so versus comparable.

Again, excluding Concentra margin in 2024. So is that also, was driving that EBITDA EBITDA margin outlook for the slight decline because the IRF margins, I guess, are going to be still kind of constrained because of the startup losses. Is the reason for the consolidated margin to be lower or is there something else to be said about other segment margins for '25? No, that's the primary driver Joanna, you're correct. Okay.

So it's pretty much the the IRBs because start up losses and then for the LPACs, should we think about those March relatively stable or how we should think about 25% versus 24% Yes, I think relatively stable is really the way to think about it.

Because I guess in that segment can you talk about the reimbursement change, the change that thresholds for the in Medicare, how you, I guess, seeing this progress through the year, the impact of that change?

Yes. You're talking about the high cost outlier threshold Yes. Yes, exactly.

Yes. Yes, I mean, our operators have done a tremendous job of managing through the significant increases we've seen in that threshold. And so if you take a look at what transpired between 2023 to 2024, there was about a $20,000 increase per patient and they've really been able to manage through that and As we take a look at it I think it went into that the increase from 'twenty four to 'twenty five was also in that same magnitude. And that started October 1, It looks like they're doing a very good job managing that too.

Okay. [indiscernible] That's great. But I guess with those changes, you think margins should be relatively flat? For the segment. Yes. Okay. And then last segment, the outpatient rehab, so these margins showed nice improvement in Q4. And, sounds like to your when you were asked your question about kind of the long term outlook, you expect the acquisition we have EBITDA to also grow double digits. So can you talk about your activity there in terms of is it just kind of sounds like you streamlining the portfolio exiting some markets maybe they don't make sense. Anything else to kind of flag in terms of like what's driving the expected growth in that segment EBITDA and also hard to think about '25? Thank you.

Yes. I think there's really two primary things that are driving that. Number one, we've mentioned there was an increase in the rate from $100 net revenue per visit up to 102 I think that's a function of some negotiated negotiations going on with the commercial contracts So that's been very helpful despite what we're seeing on Medicare cuts. So that's been very good. I think the other thing is that clinical productivity. We had mentioned, I think, in the last earnings call we've been doing a lot of work on our technology And we had a rollout in January that we think has has been very good. And would anticipate seeing additional improvement in our in our therapist productivity.

Great. Thank you so much for taking the questions.

Thank you.

That concludes today's question and answer session. I'd like to turn the call back to management for closing remarks.

No closing remarks. Everybody for your attention focus on the quarter as we kind of [indiscernible] Concentra, so that we have a clearer picture on what's going on here at Select Select appreciate your efforts.

Look forward to updating you next quarter.

This concludes today's conference call. You for participating. You may now disconnect. [indiscernible] [indiscernible]